Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses

NCT01235403 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01235403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses
Lead sponsor
UCB Pharma
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2010
Completion date
December 31, 2011
Enrollment
100 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

partial epilepsies